Publications scientifiques en 2025

Depuis le 28/07/2025
  1. Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials.
    Oliva A, Scavone C, Riccardi C, Bernardi FF, Salvo F, Mascolo A.
    Clin Transl Oncol. 2025
  2. Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case-time-control study.
    Bénard-Laribière A, Pambrun E, Kouzan S, Faillie JL, Bezin J, Pariente A.
    Thorax. 2025
  3. Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review.
    Quiles C, Taillard J, Lopez R, Geoffroy PA, Salvo F, Micoulaud-Franchi JA.
    J Sleep Res. 2025
  4. Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?
    Soeiro T, Daveluy A, Victorri-Vigneau C, Lapeyre-Mestre M, Micallef J.
    Therapie. 2025
  5. From regional signal to alert in addictovigilance.
    Daveluy A, Perino J, Gibaja V, Le Boisselier R, Batisse A, Miremont-Salamé G, Peyré A, Boucher A, Frauger E, Micallef J, Peyrière H.
    Therapie. 2025
  6. ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001.
    Perri-Plandé J, Miremont-Salamé G, Lapeyre-Mestre M, Perino J, Gibaja V, Daveluy A; French Addictovigilance Network.
    Therapie. 2025
  7. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Boulefaa D, Bagheri H, Salvo F, Rabier MB, Geniaux H, Lepelley M, Rocher F, Mahe J, Grandvillemuin A, Thai-Van H.
    Drug Saf. 2025
  8. Ethics and clinical research: How can the Ethics Committees (CPPs) and Committees for Research Ethics (CER) evolve?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2025
  9. Successful Linkage of Electronic Medical Records and National Health Data System in Type 2 Diabetes Research: Methodological Insights and Implications.
    Goff RL, Brice S, Contini A, Boussac M, Souche A, Belloc F, Coulombel N, Collin C, Gouverneur A, Molimard M.
    Pharmacoepidemiol Drug Saf. 2025
  10. Impact of psychedelics on craving in addiction: A systematic review.
    Chapron SA, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, Salvo F, Sessa B, Das R, Rolland B, Garcia-Romeu A, Auriacombe M.
    J Psychopharmacol. 2025
  11. Psychoactive cocktail consumption on Reunion Island: A case report.
    Guyon J, Maillot A, Bastard S, Weisse F, Daveluy A, Mété D.
    J Anal Toxicol. 2025
  12. Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study.
    Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski JL, Roustit M, Khouri C.
    Drug Saf. 2025
  13. Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.
    Talbot D, Diop A, Mésidor M, Chiu Y, Sirois C, Spieker AJ, Pariente A, Noize P, Simard M, Luque Fernandez MA, Schomaker M, Fujita K, Gnjidic D, Schnitzer ME.
    Stat Med. 2025
  14. Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.
    Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, Pariente A.
    Fundam Clin Pharmacol. 2025
  15. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demorgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  16. Changes in the Ambulatory Use of Antibiotics in France Due to the COVID-19 Pandemic in 2020-2022: A Nationwide Time-Series Analysis.
    Rousselot N, Brayan T, Dumartin C, Clément M, Pariente A.
    Ann Fam Med. 2025
  17. Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
    Swierczynski G, Canal-Raffin M, Tuduri L.
    Health Sci Rep. 2025
  18. The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.
    Vuotto F, Bru JP, Canaoui E, Caseris M, Chopin MCC, Cohen R, Diamantis S, Dihn A, Fillatre P, Gauzit R, Gillet Y, Jonville-Bera AP, Lafaurie M, Lesprit P, Lorrot M, Lourtet J, Maulin L, Poitrenaud D, Pariente A, Raymond J, Strady C, Stahl JP, Varon E, Welker Y, Bonnet E.
    Infect Dis Now. 2025
  19. Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Crisafulli S, Bate A, Brown JS, Candore G, Chandler RE, Hammad TA, Lane S, Maro JC, Norén GN, Pariente A, Russom M, Salas M, Segec A, Shakir S, Spini A, Toh S, Tuccori M, van Puijenbroek E, Trifirò G; Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Drug Saf. 2025
  20. The safety profile of fluoroquinolones.
    Jonville-Béra AP, Largeau B, di Meglio F, Pariente A.
    Infect Dis Now. 2025
  21. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  22. Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients: A Nationwide Population-Based Cohort Study.
    Gautier P, Elbaz M, Bezin J, Delmas C, Cherbi M, Bouisset F, Vindis C, Renoux A, Lafaurie M, Montastruc F.
    JACC Heart Fail. 2025
  23. Effect of the COVID-19 epidemic on the association between antihypertensive drug interruption and the risk of major cardiovascular event in France.
    Mathieu C, Bezin J, Pariente A.
    Am J Hypertens. 2025
  24. Medication errors in malaria management in children: insights from pharmacovigilance data in the Democratic Republic of Congo.
    Amba MN, Ntambwe EK, Biongo AE, Ntamabyaliro N, Kahunu GM, Mabiala JB, Ndosimao CN, Lutete GT, Miremont-Salamé G, Fourrier-Réglat A.
    BMC Pharmacol Toxicol. 2025
  25. Contribution of Addictovigilance data to assess adverse-events linked to psychoactive substances in children and adolescents.
    Peyrière H, Batisse A, Sam-Laï NF, Daveluy A, Fournier-Choma C, Deheul S, Chevalier C, Lacroix C, Gibaja V, Aquizerate A, Pain S, Jouanjus E, Picot MC, Nogue E.
    Br J Clin Pharmacol. 2025
  26. Letter to the Editor from Raschi et al.: "Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors".
    Raschi E, Donati M, Salvo F, Khouri C.
    J Clin Endocrinol Metab. 2025
  27. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  28. Use and Potential Misuse of GLP-1 Receptor Agonists in France: a Nationwide Cohort Study.
    du Soulier N, Pariente A, Bezin J, Grenet G, Faillie JL, de Germay S.
    Value Health. 2025
  29. Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study.
    Laurent E, Godillon L, Tassi MF, Marcollet P, Chassaing S, Decomis M, Bezin J, Laure C, Angoulvant D, Range G, Grammatico-Guillon L.
    Front Cardiovasc Med. 2025
  30. Characteristics of Drug-RElated Hospitalizations for Nursing HOme Residents: Cross-Sectional RENHO Study.
    Lopez A, Alfarano C, Lepetit M, Chebane L, Redjimi N, Couret A, Fabre D, Gardette V, Berdaï D, Lapeyre-Mestre M, Bagheri H.
    Drug Saf. 2025
  31. Experimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studies.
    Swierczynski G, Guyon J, Molimard M, Garrigou A, Baldi I, Verdun-Esquer C, Villa A, Canal-Raffin M.
    J Hazard Mater. 2025
  32. Oncologists' knowledge, practices and ethical opinions about therapeutic misconception: a French national survey.
    Haaser T, Clair S, Marty S, Berdai D, Hoarau H, Saux MC, Dreyfuss D, Maternowski PJ.
    BMC Med Ethics. 2025